|
Malignant neoplasm of breast
|
0.300 |
Biomarker
|
disease |
BEFREE |
Finally, decreased cell viability of Met receptor expressing breast cancer cells treated with delphinidin argues for a potential role of the agent in the prevention of HGF-mediated activation of various signaling pathways implicated in breast cancer.
|
18499206 |
2008 |
|
Malignant neoplasm of breast
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
The coding exons and flanking regions of HGF and MET were directly sequenced in 145 lymphedema probands, 59 unrelated women with secondary lymphedema following treatment for breast cancer, 21 individual patients with lymphedema and intestinal lymphangiectasia, and at least 159 unrelated ethnic matched control individuals.
|
18564920 |
2008 |
|
Malignant neoplasm of breast
|
0.300 |
Biomarker
|
disease |
BEFREE |
Understanding how these secondary receptors facilitate HGF/c-Met cellular responses will aid in the development of better therapeutic treatment options for breast cancer patients with elevated HGF signaling.
|
17495520 |
2007 |
|
Malignant neoplasm of breast
|
0.300 |
Biomarker
|
disease |
BEFREE |
Overexpression of LRIG1 destabilizes endogenous Met receptor in breast cancer cells and impairs their ability to respond to HGF.
|
17178829 |
2007 |
|
Malignant neoplasm of breast
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Hepatocyte growth factor enhances CXCR4 expression favoring breast cancer cell invasiveness.
|
16112111 |
2005 |
|
Malignant neoplasm of breast
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
We examined HGF, the HGF receptor (c-Met), HGFA, matriptase, and the activation inhibitors (HAI-1 and HAI-2), tissues from patients with breast cancer.
|
14734471 |
2004 |
|
Malignant neoplasm of breast
|
0.300 |
Biomarker
|
disease |
BEFREE |
This study examined the effect of NK4, a newly described HGF/SF antagonist, on HGF/SF-promoted growth of a human breast cancer.
|
12807719 |
2003 |
|
Malignant neoplasm of breast
|
0.300 |
PosttranslationalModification
|
disease |
BEFREE |
In fact, inducing disassociation of MCF-7 and T47D cells in culture by treating with HGF/scatter factor resulted in a loss of CLDN-7 expression within 24 h. Silencing of CLDN-7 expression correlated with promoter hypermethylation as determined by methylation-specific PCR (MSP) and nucleotide sequencing in breast cancer cell lines (3/3), but not in IDCs (0/5).
|
12673207 |
2003 |
|
Malignant neoplasm of breast
|
0.300 |
Biomarker
|
disease |
BEFREE |
Detection of hepatocyte growth factor/scatter factor receptor (c-Met) in axillary drainage after operations for breast cancer using reverse transcriptase-polymerase chain reaction.
|
12793903 |
2003 |
|
Malignant neoplasm of breast
|
0.300 |
Biomarker
|
disease |
BEFREE |
Retroviral ribozyme transgenes targeting HGF/SF in fibroblasts or its receptor cMET in mammary cancer cells can reduce the growth of mammary cancer and associated angiogenesis by inhibiting paracrine stromal-tumor cell interactions.
|
14519655 |
2003 |
|
Malignant neoplasm of breast
|
0.300 |
Biomarker
|
disease |
BEFREE |
HGF and Met are therefore candidate targets for therapeutic intervention in the treatment of breast cancer.
|
11934261 |
2002 |
|
Malignant neoplasm of breast
|
0.300 |
Biomarker
|
disease |
BEFREE |
Hepatocyte growth factor/scatter factor (HGF/SF), via its receptor c-MET, has been implicated to play a pivotal role in breast cancer development and progression.
|
11489839 |
2001 |
|
Malignant neoplasm of breast
|
0.300 |
Biomarker
|
disease |
BEFREE |
Inhibition of HGF/SF-induced breast cancer cell motility and invasion by the HGF/SF variant, NK4.
|
10832594 |
2000 |
|
Malignant neoplasm of breast
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
HGF/SF and c-met were determined in 73 breast cancers (median follow up: 61 months) and 10 samples of tumour-free breast tissue.
|
8837300 |
1996 |
|
Malignant neoplasm of breast
|
0.300 |
Biomarker
|
disease |
MGD |
|
|
|